Loss narrows modestly. Tango Therapeutics, Inc. (NASDAQ: TNGX) reported a loss of $0.29 per share for Q4 2025, narrower than the consensus estimate of a $0.33 loss. Shares surged 22.9% following the report, adding roughly $370 million in market value to reach a $2.05 billion market cap. Trading volume spiked to 9.8 million shares, well above typical levels for the biotechnology company.
Revenue data not disclosed. The company did not report quarterly revenue figures in its Q4 2025 earnings release. For early-stage biotechnology firms like Tango, which focus on drug development rather than commercialized products, revenue is often minimal or absent during the research phase. The market’s strong positive reaction suggests investors are focused on pipeline progress and cash runway rather than top-line growth at this stage of the company’s development.
This article was generated using AlphaStreet’s proprietary financial analysis technology and reviewed by our editorial team.